A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This 16 week study will examine the ability of olmesartan medoxomil to lower the blood
pressure of patients with moderate to severe high blood pressure in comparison to placebo.
The medication being tested has been approved by the FDA for the treatment of high blood
pressure.